The litigation began following publication of a study in July 2024 linking GLP-1 use to non-arteritic anterior ischemic optic neuropathy (NAION), a condition caused by a lack of sufficient blood flow to the optic nerve
Ipamorelin and CJC-1295, growth hormone peptides, work to increase the bodys natural store of suboptimal or depleted growth hormone releasing hormone (GHRH)
Skin may appear more hydrated, with finer lines showing subtle softening
A novel class of incretin-based therapies consisting of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual (GLP1/glucose-dependent insulinotropic polypeptide [GIP]) RAs acts by lowering blood sugar and inducing weight loss
New to the chart, so its outcomes track record is unproven
SGLT2 inhibitors remove glucose through urine, which increases calorie loss and can mimic a state of fasting